Viridian Therapeutics Inc (VRDN) - News Archive

As December 16, 2024 approaches, all eyes will be on Viridian Therapeutics, Inc. (NASDAQ: VRDN) as the biopharmaceutical company prepares to unveil the topline results from its THRIVE-2 Phase 3 clinical trial evaluating...

Viridian Therapeutics to Unveil Phase 3 Results for Promising Treatment of Chronic TED In a highly anticipated announcement, Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company with a concentrated fo...

WALTHAM, Mass. Viridian Therapeutics, Inc. (NASDAQ: VRDN), a pioneering biotechnology firm dedicated to the discovery and development of innovative medicines for serious and rare diseases, announced its financial result...

Viridian Therapeutics Set to Unveil Pivotal Data on VRDN-001 A Game-Changer in Treatment for Thyroid Eye DiseaseWALTHAM, Mass. Viridian Therapeutics, Inc. (NASDAQ: VRDN), a trailblazer in the biopharmaceutical arena, is...

Viridian Therapeutics Induces Grants to Attract Top Talent and Drive InnovationIn a recent press release, Viridian Therapeutics, a leading biopharmaceutical company specializing in the discovery and development of break...

WALTHAM, Mass. - In a significant move towards revolutionizing medical advancements for serious and rare diseases, Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company, has announced the commencement of a...

Recently, Viridian Therapeutics, a leading biotechnology company dedicated to the development of innovative medicines for serious and rare diseases, announced their participation in the prestigious 42nd Annual J.P. Morg...

Viridian Therapeutics Inc., a pioneering biotech corporation with a focus on the development of innovative medicines for severe and rare illnesses, has announced VRDN-003 as their leading subcutaneous (SC) program for t...